Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

119.47
+17.7617.46%
Post-market: 119.00-0.4700-0.39%19:49 EDT
Volume:2.78M
Turnover:327.53M
Market Cap:5.43B
PE:58.28
High:121.00
Open:115.00
Low:111.66
Close:101.71
52wk High:121.00
52wk Low:48.17
Shares:45.45M
Float Shares:44.60M
Volume Ratio:5.33
T/O Rate:6.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:6.49
PE(LYR):58.28

Loading ...

Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial

TIPRANKS
·
4 hours ago

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

GlobeNewswire
·
4 hours ago

CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform

MT Newswires Live
·
5 hours ago

Top Midday Gainers

MT Newswires Live
·
8 hours ago

Haemonetics is Maintained at Buy by BTIG

Dow Jones
·
8 hours ago

US Stocks on the MOVE-Palantir, Haemonetics

Reuters
·
8 hours ago

Why Is Haemonetics Stock (HAE) Up Over 13% Today?

TIPRANKS
·
Yesterday

Haemonetics Shares Jump 12.5% After Supply Agreement with CSL Plasma

THOMSON REUTERS
·
Yesterday

Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue

Dow Jones
·
Yesterday

Haemonetics rises 15.8%

TIPRANKS
·
Yesterday

Haemonetics Corp : Btig Raises Target Price to $130 from $110

THOMSON REUTERS
·
Yesterday

Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027

Dow Jones
·
Yesterday

Haemonetics Expands NexSys PCS Deployment with CSL Plasma

TIPRANKS
·
Yesterday

Haemonetics Says CSL Plasma Expects U.S. Rollout of Its Devices at All Centers by End-2027

Reuters
·
Yesterday

CSL to Roll Out New Haemonetics Plasma Platform Across U.S. Network

TIPRANKS
·
Yesterday

Will Real World HAE Study Change Pharvaris Stock Narrative

Simply Wall St.
·
Oct 07

BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth

GlobeNewswire
·
Oct 05

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

GlobeNewswire
·
Oct 05

Haemonetics Returned 31% On A Case The Market Never Settled

Simply Wall St.
·
Oct 04

Haemonetics (HAE) Gets a Buy from Barrington

TIPRANKS
·
Oct 01